SUPN

Supernus is a profitable-cash-flow specialty pharma masquerading, this year, as a money-loser. Revenue grew 8.6% to $719M (a fresh high above the prior $580M–$667M band), yet FY2025 swung to a -$38.5M net loss from +$73.9M, with operating income at -$62.3M. The headline is less alarming than it reads: D&A ran $91.6M against the $62.3M operating loss, so the red ink is overwhelmingly non-cash intangible amortization, and operating cash flow stayed positive at $47.3M. The balance sheet is genuinely strong — $1.06B equity against $391M total liabilities (0.37x), cash up 85% to $128M, and the legacy $23.2M long-term debt figure is from FY2012, implying negligible leverage today. This is a hold-quality franchise, not an avoid.

But the deterioration is real, not just optics. Operating cash flow fell 72.5%, and the MD&A explains why the forward picture is murkier than the top line: the Biogen ZURZUVAE collaboration requires Supernus to fund 50% of U.S. development/commercialization and to make cash payments when shared costs exceed revenue, plus front the manufacturing supply chain ahead of Biogen reimbursement — a structural working-capital and margin drag. On top of that, the Navitor (SPN-820) program is an open-ended self-funded R&D commitment after the May 2025 MOU, with an asset-purchase negotiation repeatedly extended, and a $10M Biscayne milestone due June 30, 2026.